HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Respond to This Article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Take the CE Test Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ely, E. W. Articles by Goyette, R. E. Search for Related Content PubMed PubMed Citation Articles by Ely, E. W. Articles by Goyette, R. E.

CE Article

Advances in the Understanding of Clinical Manifestations and Therapy of Severe Sepsis: An Update for Critical Care Nurses

Severe sepsis is a major public health concern and a burden on the healthcare system. Despite improvements in efforts to control the source of infection and increased recognition by healthcare providers of patients with the disease, the mortality rate remains unacceptably high, from 30% to 50%. The systemic inflammatory response syndrome criteria are used as diagnostic indicators of sepsis when they occur in patients with known or suspected infection. The outcome of a patient with severe sepsis is often related to the occurrence of sepsis-induced multiple organ dysfunction syndrome. Multiple organ dysfunction syndrome appears to result from a cascade of organism-related factors, inflammatory mediators, endothelial injury, disturbed hemostasis, and microcirculatory abnormalities. In patients with severe sepsis, derangements of inflammation and coagulation are tightly linked. Although numerous clinical trials focused on interventions in one or the other of the inflammatory and coagulation systems failed to show reduced mortality due to sepsis, a member of a new class of drugs called "cogins" was effective. In its active form, protein C has anti-inflammatory, antithrombotic, and profibrinolytic properties that can reduce organ injury associated with severe sepsis. A recombinant form of activated protein C, drotrecogin alfa (activated), significantly reduces 28-day mortality due to all causes in patients with severe sepsis and has an acceptable safety profile. This review provides an overview of severe sepsis, highlighting recent advances in treatment of the disease and the role of critical care nurses.

Notice to CE enrollees: A closed-book, multiple-choice examination following this article tests your understanding of the following objectives: Recognize definitions and terminology used to describe sepsis and its sequelae Identify factors related to the development of multiple organ dysfunction syndrome (MODS) Describe the role of recombinant human activated protein C in the treatment of severe sepsis

This article has been cited by other articles:

				K. K. Giuliano Physiological Monitoring for Critically Ill Patients: Testing a Predictive Model for the Early Detection of Sepsis Am. J. Crit. Care., March 1, 2007; 16(2): 122 - 130. [Abstract] [Full Text] [PDF]

				E. J. Bridges and S. Dukes Cardiovascular Aspects of Septic Shock: Pathophysiology, Monitoring, and Treatment Crit. Care Nurse, April 1, 2005; 25(2): 14 - 40. [Full Text] [PDF]

				J. G. Maresh, H. Xu, N. Jiang, and R. V. Shohet In Vivo Transcriptional Response of Cardiac Endothelium to Lipopolysaccharide Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1836 - 1841. [Abstract] [Full Text] [PDF]

				R. Kleinpell Advances in Treating Patients With Severe Sepsis: Role of Drotrecogin Alfa (Activated) Crit. Care Nurse, June 1, 2003; 23(3): 16 - 29. [Full Text] [PDF]

				P. E. Morris Meeting Unmet Needs in Patients With Sepsis: the Role of Drotrecogin Alfa (Activated) Am. J. Crit. Care., March 1, 2003; 12(2): 94 - 97. [Full Text] [PDF]